---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-069147"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T00:37:33.687638+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Neumora Q1 net loss $68M, secures $125M venture debt; navacaprant Ph3 data in 2026

## Summary
- Net loss $68.0M in Q1 2025, up from $53.7M in Q1 2024; R&D expense $52.2M (incl. $6.3M final Amgen costs).
- Cash, equivalents and marketable securities $249.4M as of March 31; plus $20M drawn from K2 HealthVentures extends cash runway into 2027.
- Entered $125M venture debt facility with K2 HealthVentures; $20M drawn, additional $20M available by Dec 31, 2025, $85M milestone-based.
- Navacaprant KOASTAL-3 topline data expected Q1 2026, KOASTAL-2 Q2 2026; NMRA-511 AD agitation data around end of 2025.
- M4 positive allosteric modulator (PAM) program expected to enter clinic in mid-2025.

## SEC filing metadata
- accession: 0000950170-25-069147
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000095017025069147/0000950170-25-069147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000095017025069147/nmra-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-069147
- JSON: https://secwatch.observer/filing/0000950170-25-069147.json
- Plain text: https://secwatch.observer/filing/0000950170-25-069147.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.